DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Information source: Halozyme Therapeutics
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 1 Diabetes Mellitus

Intervention: Humalog (Drug); Humulin-R (Drug); Recombinant human hyaluronidase PH20 (rHuPH20) (Drug); Liquid meal (Other)

Phase: Phase 2

Status: Completed

Sponsored by: Halozyme Therapeutics

Official(s) and/or principal investigator(s):
Linda A Morrow, M.D., Principal Investigator, Affiliation: Profil Institute for Clinical Research, Inc.


Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA) approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and Humulin-R in order to determine if it improves the absorption of these insulins to more closely mimic the body's natural increase in insulin in response to a meal.

Clinical Details

Official title: Phase II Study Evaluating Pharmacokinetics and Postprandial Glycemic Response of Subcutaneously Injected Humalog and Humulin R With/Without Co-Injected Recombinant Human Hyaluronidase Following Liquid Meal in Type1 Diabetes Mellitus Patients

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Area Under the Insulin Concentration-time Curve for the First Hour (AUC0-60)

Secondary outcome:

Maximum Serum Insulin Concentration (Cmax)

Time to Maximum Serum Insulin Concentration (Tmax)

Area Under the Blood Glucose Time-Concentration Curve Blood Glucose (AUC[BG])

Detailed description: Participants received all 4 interventions in the same order. Dose-finding visits were conducted to identify the appropriate dose of Humalog and Humulin-R. For each Humalog dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humalog, corresponding to a mass concentration of 18. 2 micrograms per milliliter (μg/mL) rHuPH20 (at final concentration of 91 U/mL of Humalog). For each Humulin-R dose-finding visit, a total of 24 U of rHuPH20 was injected SC per unit of Humulin-R, corresponding to a mass concentration of 20. 0 μg/mL rHuPH20 (at final concentration of 100 U/mL of Humulin-R).


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Male or female of age 18 to 65 years, inclusive. Females of child-bearing potential

must use a standard and effective means of birth control for the duration of the study.

- Participants with Type 1 diabetes mellitus treated with insulin for greater than or

equal to 12 months.

- Body mass index (BMI) 18. 0 to 29. 0 kilograms per meter squared (kg/m^2), inclusive.

- Glycosylated hemoglobin A1c (HbA1c) less than or equal to 10% based on local

laboratory results.

- Fasting C-peptide less than 0. 6 nanograms per milliliter (ng/mL).

- Current treatment with insulin less than 1. 2 units per kilogram per day (U/kg/day).

- Participants should be in good general health based on medical history and physical

examination, without medical conditions that might prevent the completion of study drug injections and assessments required in this protocol. Exclusion Criteria:

- Known or suspected allergy to any component of any of the study drugs in this trial.

- Previous enrollment in this trial.

- A participant who has proliferative retinopathy or maculopathy, and/or severe

neuropathy, in particular autonomic neuropathy, as judged by the Investigator.

- Clinically significant (as judged by the Investigator) active disease of the

gastrointestinal, cardiovascular (including a history of arrhythmia or conduction delays on electrocardiogram [ECG]), hepatic, neurological, renal, genitourinary, or hematological systems, or uncontrolled hypertension (diastolic blood pressure greater than or equal to 100 millimeters of mercury [mmHg] and/or systolic blood pressure greater than or equal to 160 mmHg after 5 minutes in the supine position).

- History of any illness or disease that in the opinion of the Investigator might

confound the results of the trial or pose additional risk in administering the study drugs to the participant.

- Clinically significant findings (as judged by the Investigator) in routine laboratory

data, including anemia with hemoglobin less than lower limits of normal at screening.

- Use of drugs which may interfere with the interpretation of trial results or are

known to cause clinically relevant interference with insulin action, glucose utilization, or recovery from hypoglycemia.

- Recurrent major hypoglycemia or hypoglycemic unawareness, as judged by the


- Current addiction to alcohol or substances of abuse as determined by the


- Blood donation (>500 milliliters [mL]) within the 9 weeks prior to first day of

dosing on study.

- Pregnancy, breast-feeding, the intention of becoming pregnant, or not using adequate

contraceptive measures (adequate contraceptive measures consist of sterilization, intra-uterine device [IUD], oral or injectable contraceptives or barrier methods).

- Mental incapacity, unwillingness, or language barriers precluding adequate

understanding or cooperation.

- Symptomatic gastroparesis.

- History or evidence of use of any tobacco- or nicotine-containing product within 6

months of screening or screening quantitative urine nicotine concentration >50 ng/mL.

- Receipt of any investigational drug within 4 weeks of first day of dosing in this


- Any condition (intrinsic or extrinsic) that in the judgment of the Investigator will

interfere with trial participation or evaluation of data.

Locations and Contacts

Profil Institute for Clinical Research, Inc., Chula Vista, California 91911, United States
Additional Information

Starting date: October 2008
Last updated: August 25, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017